TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company, will host a conference call and live audio webcast to disclose its financial results for the quarter ended March 31, 2014. The call and webcast will be held on Monday, May 5, 2014 at 4:30pm EDT and will be hosted by Robert Finizio, Co-Founder and Chief Executive Officer, and Dan Cartwright, Chief Financial Officer. TherapeuticsMD Inc (NYSEMKT:TXMD) stock performance was -7.06% in last session and finished the day at $4.08. Traded volume was 1.74million shares in the last session and the average volume of the stock remained 1.39million shares. The beta of the stock remained 3.93. TherapeuticsMD Inc (NYSEMKT:TXMD) insider ownership is 16.00%.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a report issued on Tuesday. They currently have a $81.00 price target on the stock. Analysts at Bank of America initiated coverage on shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in a research note on Monday, April 21st. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) dropped -6.77 percent to $65.57 Monday on volume of 907,741.00million shares. The intra-day range of the stock was $63.56 to $71.10. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has a market capitalization of $2.34billion.
Reportstack, provider of premium market research reports announces the addition of Heron Therapeutics, Inc. (NASDAQ:HRTX) – Financial and Strategic SWOT Analysis Review market report to its offering. Heron Therapeutics Inc (NASDAQ:HRTX)’s stock on Apr 28, 2014 reported a increase of 1.85% to the closing price of $12.13. Its fifty two weeks range is $6.40 -$15.82. The total market capitalization recorded $287.77million. The overall volume in the last trading session was 53,340.00million shares. In its share capital, HRTX has 23.90million outstanding shares.
Flexion Therapeutics, Inc. (NASDAQ:FLXN) was present at the 13th Annual Needham Healthcare Conference in Westin Grand Central Hotel, New York, NY. On Monday, shares of Flexion Therapeutics Inc (NASDAQ:FLXN) dropped -2.90% to close the day at $12.72. Company monthly performance is recorded as -19.29%.